Objec ve
The objec ve of this study was to analyze the outcome of surfactant replacement therapy in preterm babies with hyaline membrane disease.
Methodology
This is a prospec ve observa onal study conducted at 10 bedded neonatal unit of Pediatrics Department, Kathmandu Medical College Teaching Hospital, Sinamangal. Study th th dura on was of one year period (15 May 2017 -14 May 2018 . Preterm babies from 26 wks-35 wks of gesta on with Hyaline Membrane Disease were included in this study whereas babies with lethal congenital malforma ons eg: Meningomyelocele, Anencephaly, Gastrochisis, Diaphragma c Hernia were excluded. All preterm babies who had clinical and radiological features of HMD were considered for Surfactant Replacement Therapy (SRT). The surfactant (Survanta; Abbo Laboratories, USA; Dose: 4 ml/kg) was administered intra-tracheally according to standard procedures in four divided aliquot applying INSURE (intuba on, surfactant administra on and extuba on to Bubble CPAP) Technique. Ethical clearance was received from Ins tu onal Review Commi ee (IRC) of Kathmandu Medical College and Sta s cal analysis was done with SPSS 19 version with frequency and cross tabula on.
Results
In this study of 30 preterm babies with HMD received SRT, 47% (14) were male and 53% (16) were female. The mean birth weight of preterm babies with HMD was 1372.17 ± 395 gms and mean gesta onal age was 30.1±2.6 weeks. Among 30 preterm babies with HMD receiving SRT, 73.3% (22 babies) discharged from the hospital and 6.3% (8 babies) expired. Among eight expired babies, five died due to pulmonary hemorrhage and three died due to sep cemia with DIC. Maximum survival was seen in the gesta onal age of 30-35 wks and birth weight 1200-2100gms.
Conclusion
The use of SRT has improved the survival outcome and decreased the associated morbidi es in babies with HMD. The maximum impact of survival was seen among the preterm babies of 30-35 weeks with birth weight of 1200 -2100 grams. 
INTRODUCTION

RESULTS
In total, 30 preterm babies with HMD who received SRT were included in this study. Among them, 47% (14) were male and 53% (16) were female. Demographics and clinical characteris cs of the study popula on (n= 30) are reported in Table 1 . The mean birth weight of preterm babies with HMD receiving SRT was 1372.17 ± 395 gms and mean gesta onal age was 30.1 ±2.6 weeks. Similarly, mean Silverman's scoring for assessment of respiratory distress at 1 hour of life was 6.07 ± 1.28 and chest retrac on, tachypnea with grun ng started at 1.83 ±1.14 hr of life. In radiologically 60% (18) of babies were diagnosed as grade III HMD in Chest st X-ray. Mean age of 1 dose of SRT for 30 babies were done at nd 10.17 ± 6.9 hrs of life whereas 8 babies required 2 dose of SRT at 29.62 ± 12.2 hrs of life. A er SRT, the mean dura on of preterm babies with HMD kept under Bubble CPAP was 52.40 ± 30.7 hrs whereas mean dura on of preterm babies under mechanical ven la on was 6 ± 12.7 hrs. Table 2 .
On cross tabula on analysis, Table 3 explains co-rela on of birth weight in respect to baby's outcome. Maximum Table 1 : Demographics and clinical parameters of babies in NICU (n = 30) survival was seen among babies with the birth weight of 1200gms and more. Out of 22 survived babies, 15 were with birth weight 1200-2100gms. Similarly, Table 4 explains co-rela on of gesta onal age with respect to baby's outcome. Out of 22 survived babies, 13 preterm babies were of 30-35 wks of gesta onal age. The result showed maximum survival of babies were found in-between the gesta onal age 30-35 wks and birth weight 1200-2100gms respec vely. Table 2 : N eonatal parameters (n = 30) Kathmandu Medical College Teaching Hospital), survival rate a er SRT in preterm babies with HMD was 73.3% (22 out of 30 preterm babies) and common co-morbid condi on observed were pulmonary hemorrhage (62.5%) and Sepsis with DIC (37.5%). It was also so apathe c that only 17.7% (5) In this study at Kathmandu Medical College Teaching Hospital, mean birth weight of babies receiving SRT was 1372.17 ± 395 gms, mean gesta onal age 30.1 ±2.6 weeks and mean hospital stay 14.95 ± 6.25 days sugges ve of comparable outcomes in both studies. Survival outcome in this study showed birth weight≥ 1200 gms and gesta on ≥ 30wks, which was quite similar to the Narang A et al study (Gesta onal age ≥ 30 wks and birth weight≥ 1000gms).
A mul centre study in Newyork by Kendig JW et al has shown "rescue" surfactant replacement therapy is equally efficacious and comparable as early 'prophylac c' surfactant 16 replacement therapy for preterm babies with HMD. So, in developing countries like Nepal, due to lack of affordability, "rescue" surfactant replacement therapy is usually prac ced and in this study at Kathmandu Medical College Teaching Hospital also "rescue" surfactant replacement therapy among 30 preterm babies with HMD was prac ced..
CONCLUSION
Probably this is the first study done in Nepal highligh ng the posi ve impact of SRT in preterm babies with HMD. The use of SRT has improved the survival outcome and decreased the associated morbidi es in babies with HMD. The maximum impact of survival was seen among the preterm babies of 30-35 weeks gesta on and birth weight group of 1200 -2100 grams. This study has also shown that SRT followed by Bubble CPAP has significantly reduced the subsequent need for mechanical ven la on.
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